[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344835-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344835-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","an-epidemiological-study-estimating-the-burden-of-cancer-risk-in-patients-with-raynauds-phenomenon","An epidemiological study estimating the burden of cancer risk in patients with Raynaud’s phenomenon","","Raynaud’s phenomenon (RP) is a common vasospastic condition that may be linked to cancer and systemic autoimmune rheumatic diseases (SARDs). This study estimated cancer risk in RP patients without known SARDs, intended to resemble “primary” RP. Using North American electronic healthcare records, RP cohorts were defined by at least two ICD I73.0 codes with SARDs excluded, then matched to IBS-like comparators using propensity-score Cox models. RP showed a higher hazard of any cancer across both age strata, with increased thorax, skin, and haematological risks, while digestive cancer risk decreased.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/an-epidemiological-study-estimating-the-burden-of-cancer-risk-in-patients-with-raynauds-phenomenon/344835/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/an-epidemiological-study-estimating-the-burden-of-cancer-risk-in-patients-with-raynauds-phenomenon/344835.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How did the study define Raynaud’s phenomenon (RP) and exclude confounding SARDs?","Question",{"text":63,"@type":64},"RP was defined using at least two ICD codes (I73.0), and cases with known SARDs were excluded. This aimed to estimate cancer risk in RP patients without known autoimmune rheumatic disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the main outcomes used to assess cancer risk in RP?",{"text":68,"@type":64},"The primary outcome was any cancer event. Secondary outcomes were rates of specific cancer types, including head and neck, digestive, thorax, skin, breast, haematological, and male/female genital cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about cancer risk across different age groups?",{"text":72,"@type":64},"RP was associated with a higher hazard of any cancer in both age groups: \u003C45 years (HR 1.11) and ≥45 years (HR 1.08). Cancer-specific analyses also showed increased risk for thorax, skin, and haematological cancers, alongside a decreased risk for digestive cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344835,1790242695,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Clinical Rheumatology (2026) 45:1651–1656  \n[https://doi.org/10.1007/s10067-026-07961-y](https://doi.org/10.1007/s10067-026-07961-y)  \n\n| \u003Cbr>BRIEF REPORT\u003Cbr>\u003Cbr>An epidemiological study estimating the burden of cancer risk in patients with Raynaud’s phenomenon\u003Cbr>Michael Hughes1,2,3 · Edward Jude4,5,6 · Zsuzsanna H. McMahan7 · Uazman Alam8,9 · Barbara Ruaro10 · Sizheng Steven Zhao1,3\u003Cbr>Received: 23 December 2025 / Revised: 17 January 2026 / Accepted: 19 January 2026 / Published online: 29 January 2026 © The Author(s) 2026\u003Cbr>Abstract\u003Cbr>Introduction/Objective Raynaud’s phenomenon (RP) is a common vasospastic condition that may develop secondary to cancer and/or in association with systemic autoimmune rheumatic diseases (SARDs) . We aimed to estimate the risk of cancer in RP without known SARDs, phenotypically akin to ‘primary’ RP.\u003Cbr>Methods A cohort study using data from North American electronic healthcare organization records. RP was defined using ≥ 2 ICD (I73.0) codes, excluding SARDs. Comparators had ≥ 2 irritable bowel syndrome ICD (K58) codes: selected with similar epidemiology to RP, and without any known excess in cancer risk. Cohorts were stratified by age (\u003C 45 and ≥ 45 years) . Our primary outcome was any cancer event. Secondary outcomes were rates of specific cancers: head and neck, digestive, thorax, skin, breast, haematological, male/female genital. Risk of each outcome was compared using 1:1 propensity score-matched Cox proportional hazard models.\u003Cbr>Results Among 34,582 (\u003C 45 years) and 68,836 (≥ 45 years) matched pairs, the hazard ratio (HR) of any cancer was higher in RP: \u003C 45 [1.11 (1.03, 1.19)] and ≥ 45 [1.08 (1.05, 1.11)] . Cancer-specific risks were calculated. RP was associated in both age groups with increased risk of thorax (HR 2.077 & 1.433), skin (HR 1.202 &1.213), and haematological (HR 1.647 & 1.338) cancers. RP was associated with decreased risk of digestive cancer (HR 0.686 & 0.894) .\u003Cbr>Conclusion RP was associated with an increased risk of cancer, independent of age. We also describe varying cancer-specific risks. Future research is warranted to confirm and explore these novel observations, including potentially shared pathobiological mechanisms. |\n| --- |\n| Key Points\u003Cbr>• RP was associated with an overall increased risk of all cancers in younger (\u003C45years) and older (≥45 years) individuals.\u003Cbr>• There was an increased risk of certain (e.g., thorax, skin, and haematological) cancers with RP.\u003Cbr>• A reduced risk of cancer was also noted for certain cancers, especially GI-related.\u003Cbr>• Future research should confirm and explore these observations, including the pathobiology underpinning potential cancer risk in RP. |\n\nKeywords Autoimmunity · Cancer · Malignancy · Raynaud’s phenomenon · Rheumatology · Systemic sclerosis  \n*  \n1  \n2  \n3  \n4  \nMichael Hughes  \n[Michael.hughes-6@manchester.ac.uk](Michael.hughes-6@manchester.ac.uk)  \nCentre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Stopford Building, Oxford Road, Manchester, UK  \nDepartment of Rheumatology, Northern Care Alliance NHS  \nFoundation Trust, Salford Care Organisation, Salford, UK NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK  \nTameside and Glossop Integrated Care NHS Foundation Trust, Ashton under Lyne, UK  \n5 University of Manchester, Manchester, UK  \n6 Manchester Metropolitan University, Manchester, UK  \n7 Department of Medicine, Division of Rheumatology, UTHealth Houston, Houston, TX, USA  \n8 Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK  \n9 Department of Medicine, University Hospital Aintree, Liverpool University NHS Foundation Trust, Liverpool, UK  \n10 Department of Medical Surgical and Health Sciences, Hospital of Cattinara, University of Trieste,","cbCaiv9a65oBJwp6","https://ap.wps.com/l/cbCaiv9a65oBJwp6","pdf",751567,"English","# Key Points\n## Overall cancer risk\n## Cancer subtypes associated with RP\n## Cancer types with reduced risk\n# Introduction\n## Primary vs secondary Raynaud’s phenomenon\n## RP and cancer-related mechanisms\n# Methods\n## Cohort definition and matching\n## Outcomes and statistical approach\n# Results\n## Any cancer hazard ratios by age\n## Cancer-specific hazard ratios\n# Conclusion\n## Summary and future research directions","[{\"question\":\"How did the study define Raynaud’s phenomenon (RP) and exclude confounding SARDs?\",\"answer\":\"RP was defined using at least two ICD codes (I73.0), and cases with known SARDs were excluded. This aimed to estimate cancer risk in RP patients without known autoimmune rheumatic disease.\"},{\"question\":\"What were the main outcomes used to assess cancer risk in RP?\",\"answer\":\"The primary outcome was any cancer event. Secondary outcomes were rates of specific cancer types, including head and neck, digestive, thorax, skin, breast, haematological, and male/female genital cancers.\"},{\"question\":\"What did the results show about cancer risk across different age groups?\",\"answer\":\"RP was associated with a higher hazard of any cancer in both age groups: \\u003c45 years (HR 1.11) and ≥45 years (HR 1.08). Cancer-specific analyses also showed increased risk for thorax, skin, and haematological cancers, alongside a decreased risk for digestive cancers.\"}]","An epidemiological study estimating the burden of cancer risk in patients with Raynaud’s phenomenon | PDF",1790055407,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/513bd2e961c772416e9472d32d92ecbe.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a7a5cac5b11a0be158cdd6e966de248.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d221d2a1f40033de61d067d513e00350.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5e500bcdb1ff77a8cbc878efb1064be.webp",980,1301]